Jefferies Believes Zimmer Biomet Holdings (NYSE: ZBH) Won’t Stop Here

By Austin Angelo

In a report released yesterday, Raj Denhoy from Jefferies reiterated a Buy rating on Zimmer Biomet Holdings (NYSE: ZBH), with a price target of $148. The company’s shares closed yesterday at $127.89, close to its 52-week high of $133.21.

According to, Denhoy is a top 100 analyst with an average return of 17.7% and a 76.1% success rate. Denhoy covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Varian Medical Systems, and Edwards Lifesciences.

Currently, the analyst consensus on Zimmer Biomet Holdings is Moderate Buy and the average price target is $134.45, representing a 5.1% upside.

In a report issued on June 21, RBC Capital also reiterated a Buy rating on the stock with a $140 price target.

The company has a one year high of $133.21 and a one year low of $95.63. Currently, Zimmer Biomet Holdings has an average volume of 377.7K.

Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is negative on the stock. Earlier this month, Sang Yi, the President of ZBH sold 17,731 shares for a total of $2,208,490.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Zimmer Biomet Holdings, Inc. designs, manufactures and markets orthopaedic reconstructive products, sports medicine, extremities and trauma products; craniomaxillofacial and thoracic products; dental implants; and related surgical products. The company operates through three geographical segments: America, Europe and Asia Pacific.